In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma

Histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) are in early clinical development for multiple myeloma (MM) therapy. Despite all encouraging pre-clinical data, clinical activity of HDACi and DNMTi is mostly lacking. To optimize the trials, characterization of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Maes, Ken, De Smedt, Eva, Kassambara, Alboukadel, Hose, Dirk, Seckinger, Anja, Van Valckenborgh, Els, Menu, Eline, Klein, Bernard, Vanderkerken, Karin, Moreaux, Jérôme, De Bruyne, Elke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413656/
https://www.ncbi.nlm.nih.gov/pubmed/25669970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413656/
https://www.ncbi.nlm.nih.gov/pubmed/25669970

Ejemplares similares